Erik Vernet

699 total citations
17 papers, 405 citations indexed

About

Erik Vernet is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Erik Vernet has authored 17 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 9 papers in Radiology, Nuclear Medicine and Imaging and 4 papers in Oncology. Recurrent topics in Erik Vernet's work include Monoclonal and Polyclonal Antibodies Research (9 papers), Protein purification and stability (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Erik Vernet is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (9 papers), Protein purification and stability (4 papers) and Viral Infectious Diseases and Gene Expression in Insects (3 papers). Erik Vernet collaborates with scholars based in Denmark, Sweden and United States. Erik Vernet's co-authors include Torbjörn Gräslund, M. Sundström, Vitaliy O. Kaminskyy, Lukas M. Orre, Boris Zhivotovsky, Janne Lehtiö, Elena Panizza, Gianni Carraro, Emma Lundberg and Mats Wikström and has published in prestigious journals such as Molecular Cell, Analytical Biochemistry and Oncogene.

In The Last Decade

Erik Vernet

17 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Erik Vernet Denmark	9	278	71	65	51	44	17	405
Jiann-Shiun Lai Taiwan	9	293 1.1×	79 1.1×	42 0.6×	80 1.6×	110 2.5×	16	474
Kamel Chettab France	14	180 0.6×	56 0.8×	58 0.9×	142 2.8×	81 1.8×	31	479
Sylvia Metzner Germany	9	310 1.1×	106 1.5×	35 0.5×	132 2.6×	50 1.1×	12	587
Orit Foord United States	10	299 1.1×	77 1.1×	48 0.7×	172 3.4×	34 0.8×	13	436
Richard Kirkman United States	11	221 0.8×	45 0.6×	26 0.4×	46 0.9×	57 1.3×	18	379
Gauri Muradia Canada	12	196 0.7×	32 0.5×	26 0.4×	26 0.5×	40 0.9×	18	405
Elena Fernández Fernández Ireland	12	405 1.5×	56 0.8×	42 0.6×	38 0.7×	30 0.7×	19	629
Luisa Calvanese Italy	13	232 0.8×	23 0.3×	26 0.4×	50 1.0×	36 0.8×	32	358
Robert P. Vanderwaal United States	13	429 1.5×	56 0.8×	54 0.8×	112 2.2×	14 0.3×	18	585
Sergey S. Larin Russia	13	199 0.7×	52 0.7×	46 0.7×	108 2.1×	107 2.4×	45	439

Countries citing papers authored by Erik Vernet

Since Specialization

Citations

This map shows the geographic impact of Erik Vernet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Vernet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Vernet more than expected).

Fields of papers citing papers by Erik Vernet

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Vernet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Vernet. The network helps show where Erik Vernet may publish in the future.

Co-authorship network of co-authors of Erik Vernet

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Vernet. A scholar is included among the top collaborators of Erik Vernet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Vernet. Erik Vernet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Climente-González, Héctor, Min Oh, Urszula Chajewska, et al.. (2025). Interpretable machine learning leverages proteomics to improve cardiovascular disease risk prediction and biomarker identification. Communications Medicine. 5(1). 170–170. 2 indexed citations

Fu, Guangsen, Wafa Hassouneh, Ayesha Misquith, et al.. (2023). Choice of fusion proteins, expression host, and analytics solves difficult‐to‐produce protein challenges in discovery research. Biotechnology Journal. 19(1). e2300162–e2300162. 2 indexed citations

Vernet, Erik, et al.. (2020). Engineering Xaa-Pro dipeptidyl aminopeptidase for specific cleavage of glucagon and glucagon-like peptide 1 from fusion proteins. Protein Expression and Purification. 170. 105590–105590. 1 indexed citations

Rahbarizadeh, Fatemeh, et al.. (2018). Anti–HER2 single domain antibody-conjugated dendrimers for targeted delivery of truncated-Bid transgene to breast cancer cells. Journal of Bioactive and Compatible Polymers. 34(1). 39–57. 4 indexed citations

Vernet, Erik, Gina Popa, Irina Pozdnyakova, et al.. (2016). Large-Scale Biophysical Evaluation of Protein PEGylation Effects: In Vitro Properties of 61 Protein Entities. Molecular Pharmaceutics. 13(5). 1587–1598. 14 indexed citations

Brandt, Nina, Hayley M. O’Neill, Maximilian Kleinert, et al.. (2015). Leukemia inhibitory factor increases glucose uptake in mouse skeletal muscle. American Journal of Physiology-Endocrinology and Metabolism. 309(2). E142–E153. 28 indexed citations

Vernet, Erik, et al.. (2014). Understanding the Photochemical Pathway of In Vitro Target Delivery of Aluminium Phthalocyanine: A Mechanistic Approach Using Radical Reaction Chemistry. ChemPlusChem. 79(5). 671–679. 2 indexed citations

Francavilla, Chiara, Kristoffer Rigbolt, Kristina B. Emdal, et al.. (2013). Functional Proteomics Defines the Molecular Switch Underlying FGF Receptor Trafficking and Cellular Outputs. Molecular Cell. 51(6). 707–722. 111 indexed citations

Orre, Lukas M., Elena Panizza, Vitaliy O. Kaminskyy, et al.. (2013). S100A4 interacts with p53 in the nucleus and promotes p53 degradation. Oncogene. 32(49). 5531–5540. 76 indexed citations

10.

Kotzsch, Alexander, Erik Vernet, M. Hammarstrom, et al.. (2011). A secretory system for bacterial production of high‐profile protein targets. Protein Science. 20(3). 597–609. 36 indexed citations

11.

Vernet, Erik, Jørgen Sauer, Andreas Breenfeldt Andersen, Knud J. Jensen, & Björn G. Voldborg. (2011). Predictive mutagenesis of ligation-independent cloning (LIC) vectors for protein expression and site-specific chemical conjugation. Analytical Biochemistry. 414(2). 312–314. 4 indexed citations

12.

Vernet, Erik, Alexander Kotzsch, Björn G. Voldborg, & M. Sundström. (2010). Screening of genetic parameters for soluble protein expression in Escherichia coli. Protein Expression and Purification. 77(1). 104–111. 13 indexed citations

13.

Lundberg, Emma, Feifan Yu, Seiji Shibasaki, et al.. (2010). Selection and characterisation of affibody molecules inhibiting the interaction between Ras and Raf in vitro. New Biotechnology. 27(6). 766–773. 11 indexed citations

14.

Li, Jinɡjinɡ, Emma Lundberg, Erik Vernet, et al.. (2010). Selection of affibody molecules to the ligand‐binding site of the insulin‐like growth factor‐1 receptor. Biotechnology and Applied Biochemistry. 55(2). 99–109. 34 indexed citations

15.

Vernet, Erik, Emma Lundberg, Mikaela Friedman, et al.. (2009). Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain. New Biotechnology. 25(6). 417–423. 4 indexed citations

16.

Vernet, Erik, et al.. (2008). Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule. Journal of Immunological Methods. 338(1-2). 1–6. 8 indexed citations

17.

Mallolas, Josep, Josep M. Miró, Erik Vernet, et al.. (1993). Primary prophylaxis for Pneumocystis carinii pneumonia: a randomized trial comparing cotrimoxazole, aerosolized pentamidine and dapsone plus pyrimethamine.. PubMed. 7(1). 59–64. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact